NASDAQ: HCATHealth Catalyst Inc Stock
$2.29+0.21 (+10.1%)
Updated Jul 6, 2026
HCAT Price
$2.29
Fair Value Price
$2.89
Market Cap
$169.22M
52 Week Low
$0.96
52 Week High
$4.12
P/E
-0.61x
P/B
1.22x
P/S
0.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$302.48M
Earnings
-$265.26M
Gross Margin
49.9%
Operating Margin
-81.71%
Profit Margin
-87.7%
Debt to Equity
1.98
Operating Cash Flow
$19M
Beta
1.67
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
HCAT Overview
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HCAT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
C
HCAT
Ranked#22 of 42
Ranked#22 of 42
Be the first to know about important HCAT news, forecast changes, insider trades & much more!
HCAT News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HCAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HCAT ($2.29) is undervalued by 20.81% relative to our estimate of its Fair Value price of $2.89 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HCAT ($2.29) is significantly undervalued by 20.81% relative to our estimate of its Fair Value price of $2.89 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HCAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HCAT due diligence checks available for Premium users.
Valuation
HCAT fair value
Fair Value of HCAT stock based on Discounted Cash Flow (DCF)
Price
$2.29
Fair Value
$2.89
Undervalued by
20.81%
HCAT ($2.29) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HCAT ($2.29) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HCAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HCAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.61x
Industry
13.03x
Market
6.94x
HCAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.22x
Industry
3.44x
HCAT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HCAT's financial health
Profit margin
Revenue
$70.8M
Net Income
-$111.0M
Profit Margin
-156.9%
HCAT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HCAT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$412.2M
Liabilities
$274.1M
Debt to equity
1.98
HCAT's short-term assets ($182.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HCAT's short-term assets ($182.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HCAT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HCAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$18.5M
Investing
-$9.4M
Financing
-$4.0k
HCAT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HCAT vs Health Information Service Stocks
Health Catalyst Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.